Medicine
Myoview 0.23 mg powder for injection
Myoview 0.23 mg powder for injection is a prescription medicine containing Tetrofosmin for intravenous use, marketed by GE Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store the kit at 2° to 8°C (36° to 46°F), protected from light. Store the…
Key facts
- Active ingredient (INN)
- Tetrofosmin
- Brand
- Myoview
- Strength
- 0.23 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 5 vials
- Marketing authorisation holder
- GE Healthcare
- Manufacturer
- GE Healthcare
- Origin register
- US FDA, United States
- Storage
- Store the kit at 2° to 8°C (36° to 46°F), protected from light. Store the radiolabeled vial at 2° to 25°C (36° to 77°F), using appropriate radiation shielding. This reagent kit is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State, store and dispose of technetium Tc99m tetrofosmin in accordance with these…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 February 1996
- Identifiers
- DailyMed set ID 4a8e5ed7-57f4-4d48-93cd-5f307207a3a0NDC 17156-024Application NDA020372
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 vial in 1 kit / 1 injection, powder, lyophilized, for solution in 1 vial | 17156-024-05 | GE Healthcare | 1 March 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tetrofosmin
Clinical summary
Tetrofosmin is a prescription medicine indicated for the following, among other approved uses. It is available as powder for injection for intravenous use. MedsAcross supplies Tetrofosmin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TetrofosminFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Myoview prescribing information (GE Healthcare) · U.S. National Library of Medicine, DailyMed
Need Myoview 0.23 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.